Human glioma cell sensitivity to the sequence-specific alkylating agent methyl-lexitropsin

Area of Science:

• Molecular Biology
• Cancer Research
• DNA Damage and Repair

Background:

• Understanding DNA adduct cytotoxicity is crucial for brain tumor resistance mechanisms and developing antiresistance strategies.
• Methyl-lexitropsin (Me-lex) is a sequence-specific alkylating agent primarily forming 3-methyladenine (3-meA) DNA lesions.

Purpose of the Study:

• To characterize the cytotoxicity of Me-lex in human glioma cells.
• To investigate the roles of O(6)-methylguanine (O(6)-meG)-DNA methyltransferase (MGMT), alkyladenine DNA glycosylase (AAG), and Ape1 in Me-lex resistance.

Main Methods:

• Quantified Me-lex cytotoxicity across 10 human glioma cell lines with varying MGMT and mismatch repair activity.
• Utilized antisense suppression of AAG and Ape1 to assess the contribution of 3-meA and abasic sites to Me-lex lethality.
• Measured abasic site formation.

Main Results:

• Me-lex exhibited wide-ranging cytotoxicity among glioma cell lines.
• MGMT-proficient lines showed unexpected resistance to Me-lex.
• Suppression of AAG enhanced Me-lex killing and reduced abasic sites, indicating 3-meA is a lethal lesion.
• Suppression of Ape1 increased Me-lex killing and abasic sites, suggesting cytotoxicity of these derivative lesions.
• MGMT ablation did not affect Me-lex cytotoxicity.

Conclusions:

• 3-methyladenine (3-meA) is a lethal DNA lesion in human glioma cells, and AAG promotes resistance.
• Abasic sites, arising from 3-meA repair, are also cytotoxic, with Ape1 contributing to resistance against these lesions.
• Factors associated with MGMT expression, beyond O(6)-meG repair, influence Me-lex resistance.
• Me-lex holds potential as an adjuvant therapy for gliomas.
• Inhibitors of AAG and Ape1 could be valuable in overcoming alkylating agent resistance.